富祥藥業(300497.SZ):公司與天賜材料、新宙邦等均已形成良好合作關係 現滿產滿銷
格隆匯7月10日丨富祥藥業(300497.SZ)近期在接待機構調研時表示,2022年公司鋰電池電解液添加劑業務實現營收14,746.64萬元,佔公司營業收入比重8.95%。2023年以來,公司VC等鋰電池電解液添加劑業務營收持續增長,且在質量和成本控制方面均有較大進步。截止目前,公司與天賜材料、新宙邦等國內主要電解液生產商均已形成了良好的合作關係,現滿產滿銷。後續公司將持續優化產品生產工藝,改進生產裝備,提升設備自動化水平,同時積極打造循環經濟體系,降低綜合生產成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.